*FDA Approves Spravato as Standalone Treatment for Depression
In a significant advancement for mental health treatment, the U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant major depressive disorder (MDD). This decision, announced on January 21, 2025, marks a pivotal shift in the management of depression, offering new hope […]
*A New Era in Pain Management
In a groundbreaking development, the U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine), a novel non-opioid pain medication developed by Vertex Pharmaceuticals. This approval marks the first introduction of a new class of pain treatment in over two decades, offering a promising alternative for managing moderate to severe acute pain without the risks […]
*Personalized Weight Loss Consultations with My Virtual Physician
Losing weight isn’t just about diet and exercise—it’s about having the right medical support, personalized care, and access to the best treatment options. At My Virtual Physician, we are committed to helping patients achieve their weight loss goals through comprehensive virtual consultations, including access to GLP-1 medications, both compounded and non-compounded. Why GLP-1 Medications for […]
*Navigating GLP-1 Medications for Weight Loss: Safety, Effectiveness, and What You Need to Know
Losing weight is a journey that requires the right combination of medical support, lifestyle changes, and safe, effective treatments. GLP-1 receptor agonists, such as semaglutide and tirzepatide, have transformed obesity management by helping patients regulate appetite and improve metabolic health. However, with growing demand for these medications, it’s essential to understand the differences between FDA-approved […]